Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report

J Antimicrob Chemother. 2022 Feb 23;77(3):851-853. doi: 10.1093/jac/dkab424.

Authors

Minh Patrick Lê^{1

2}, Valentine Marie Ferré^{3

4}, Fabienne Mazy⁵, Agnès Bourgeois-Moine⁵, Florence Damond^{3

4}, Sophie Matheron^{4

6}, Diane Descamps^{3

4}, Jade Ghosn^{4

6}, Gilles Peytavin^{1

4}

Affiliations

¹ AP-HP, Bichat Claude Bernard Hospital, Pharmacology Department, 75018 Paris, France.
² INSERM, UMRS-1144, Université de Paris, 75006 Paris, France.
³ AP-HP, Bichat Claude Bernard Hospital, Virology Department, 75018 Paris, France.
⁴ IAME, INSERM, UMR 1137, Université de Paris, 75018 Paris, France.
⁵ AP-HP, Bichat Claude Bernard Hospital, Gynaecology and Obstetrics Department, 75018 Paris, France.
⁶ AP-HP, Bichat Claude Bernard Hospital, Infectious and Tropical Diseases Department, 75018 Paris, France.

PMID: 34792155
DOI: 10.1093/jac/dkab424

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Amides
Female
HIV-1*
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Piperazines
Pregnancy
Pregnant Women
Pyridones

Substances

Amides
Heterocyclic Compounds, 3-Ring
Piperazines
Pyridones
bictegravir